Category Archives: Pharmaceuticals

Healthcare stocks bounce back Friday after really messy week, but still licking their wounds from recent global selloff.

After having their worst week in recent memory, with the NASDAQ HealthCare Index (IXHC) now down 8.6% since just Sept. 28, some healthcare stocks nonetheless blossomed with stupendous upswings. But… Read more »

Why Galapagos’s Phase 3 rheumatoid arthritis success is largely irrelevant.

The News: Galapagos NV (Mechelen BEL) and Gilead Sciences Inc. (Foster City CA) have reported positive results from a Phase 3 trial testing Galapagos’s lead drug candidate in patients with… Read more »

Five more biotechs and one device maker close out 3rd quarter IPOs this week.

There are as many as five more biotech IPOs and one medical device maker pricing this week, raising up to $535 million. Even if two are postponed, it will still… Read more »

Eureka Thera’s CAR-T treatment shrinks liver cancer in small study. What’s the big deal? Just ask Sloan-Kettering and Germany’s Boehringer.

The News: Eureka Therapeutics Inc., a closely held biotechnology company, said that liver cancer patients getting its CAR-T therapy responded to the treatment, one of the first times the immune-system… Read more »

Novo Nordisk buys UK biotech startup for $800M, fueling blockbuster hopes for “smart” insulin. This Danish behemoth is a smart Buy.

The News: Novo Nordisk A/S (Bagsvaerd) has acquired UK start-up Ziylo Ltd. (Bristol) in a deal worth up to $800 million in a bid to develop the world’s first “smart”… Read more »

India’s huge pharma/consumer health market in crosshairs of world’s biggest drugmakers. China, Japan, Korea lurking as Asia joins fray with West.

The News: GlaxoSmithKline PLC‘s (London) Indian consumer health unit is drawing the attention of more big-name suitors as the magnitude of the potential there is coming into clearer focus. After… Read more »

Korean push into biotech space meant to challenge China, as ViroMed buys US plant for new gene-therapy development. High risk/reward bet, only for the brave.

The News: ViroMed Co. Ltd., the Korean biotech, has seen companies miss out on approvals for novel therapies because the FDA had problems with their manufacturing processes. With its first treatment… Read more »

ViiV Healthcare’s success with monthly combo HIV med making Gilead sweat over its HIV franchise. After World Cup fiasco, England chasing California in $$$$/rep race.

The News: GlaxoSmithKline PLC’s (London) ViiV Healthcare unit now has results to support a two-drug monthly injection co-developed with Johnson & Johnson (New Brunswick NJ) as it pushes ahead with its ambition… Read more »

Solution to China’s vaccine scandal now in the hands of rising blockchain maven VeChain. Buy a few tokens?

The News: A new production scandal has undermined Chinese citizens’ confidence in domestically made vaccines, and the tech community is suggesting the solution may lie in a highly touted technology: blockchain…. Read more »

Organoids have landed in Austria: New 3D-printed placenta poised to solve life-threatening questions. But a little too late after Dutch trial runs amok.

The News: Austrian researchers have created a miniature 3D model of the human placenta, which could help us understand the causes of pregnancy complications. The human placenta plays a vital… Read more »